Avalo Therapeutics, Inc.
—- Market cap
- —
- Debt
- +$20.26M
- Cash
- −$98.34M
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: AVTX stock price vs EXC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EXC's multiple
Needs EXC P/S.
Implied fair value · at AVTX's multiple
Needs AVTX P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AVTX FY 2025 (ended Dec 31, 2025) · EXC FY 2025 (ended Dec 31, 2025).
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
AVALO THERAPEUTICS, INC. · implied price per share
Bear
$1.24
Base
$1.45
Bull
$1.67
EXELON CORPORATION · implied price per share
Bear
$31.51
Base
$37.07
Bull
$42.63
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.24x
1.77x
Net debt / EBITDA
Leverage against operating earnings
1.03x
4.91x
Cash and equivalents
Liquid reserves on the balance sheet
$98.34M
$626.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CytomX Therapeutics, Inc.
AVTX vs CTMX
IDEAYA Biosciences, Inc.
AVTX vs IDYA
Ocugen, Inc.
AVTX vs OCGN
CLOVER HEALTH INVESTMENTS, CORP. /DE
AVTX vs CLOV
Citius Pharmaceuticals, Inc.
AVTX vs CTXR
SOUTHERN CO
AVTX vs SO
ENTERGY CORP /DE/
AVTX vs ETR
CONSOLIDATED EDISON INC
AVTX vs ED
Duke Energy Corporation
AVTX vs DUK
AMERICAN ELECTRIC POWER CO INC
AVTX vs AEP
DOMINION ENERGY, INC
AVTX vs D
$20.26M
$51.09B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.